EYPT
Price:
$7.97
Market Cap:
$426.54M
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible...[Read more]
Industry
Biotechnology
IPO Date
2005-01-27
Stock Exchange
NASDAQ
Ticker
EYPT
According to EyePoint Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.48. This represents a change of -49.74% compared to the average of -8.91 of the last 4 quarters.
The mean historical PE Ratio of EyePoint Pharmaceuticals, Inc. over the last ten years is -2.38. The current -4.48 PE Ratio has changed 18.72% with respect to the historical average. Over the past ten years (40 quarters), EYPT's PE Ratio was at its highest in in the September 2014 quarter at 1.58. The PE Ratio was at its lowest in in the December 2016 quarter at -218.07.
Average
-2.38
Median
-2.92
Minimum
-12.38
Maximum
17.45
Discovering the peaks and valleys of EyePoint Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.08%
Maximum Annual PE Ratio = 17.45
Minimum Annual Increase = -295.66%
Minimum Annual PE Ratio = -12.38
Year | PE Ratio | Change |
---|---|---|
2023 | -12.38 | 1.08% |
2022 | -1.05 | -80.95% |
2021 | -5.51 | 243.31% |
2020 | -1.60 | -37.52% |
2019 | -2.57 | 41.99% |
2018 | -1.81 | -44.69% |
2017 | -3.27 | -21.28% |
2016 | -4.15 | -123.80% |
2015 | 17.45 | -295.66% |
2014 | -8.92 | 20.88% |
The current PE Ratio of EyePoint Pharmaceuticals, Inc. (EYPT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-6.31
5-year avg
-4.62
10-year avg
-2.38
EyePoint Pharmaceuticals, Inc.’s PE Ratio is less than Ocuphire Pharma, Inc. (-2.20), less than Reviva Pharmaceuticals Holdings, Inc. (-1.10), greater than Protalix BioTherapeutics, Inc. (-4.99), less than SELLAS Life Sciences Group, Inc. (-1.99), greater than Alpha Tau Medical Ltd. (-5.75), less than HCW Biologics Inc. (-0.69), greater than Innate Pharma S.A. (-14.83), less than Orchestra BioMed Holdings, Inc. (-3.61), less than Chimerix, Inc. (-0.93), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than X4 Pharmaceuticals, Inc. (7.41), greater than Mereo BioPharma Group plc (-18.18), greater than Terns Pharmaceuticals, Inc. (-6.06), less than ALX Oncology Holdings Inc. (-0.58), less than Cabaletta Bio, Inc. (-2.34), less than Viracta Therapeutics, Inc. (-0.21), less than Biomea Fusion, Inc. (-1.83), less than Acumen Pharmaceuticals, Inc. (-2.06), less than HOOKIPA Pharma Inc. (-1.22),
Company | PE Ratio | Market cap |
---|---|---|
-2.20 | $31.44M | |
-1.10 | $44.68M | |
-4.99 | $73.54M | |
-1.99 | $76.56M | |
-5.75 | $148.54M | |
-0.69 | $26.62M | |
-14.83 | $186.99M | |
-3.61 | $212.20M | |
-0.93 | $78.52M | |
-7.39 | $1.25B | |
7.41 | $109.78M | |
-18.18 | $664.26M | |
-6.06 | $549.60M | |
-0.58 | $100.60M | |
-2.34 | $208.10M | |
-0.21 | $9.50M | |
-1.83 | $256.37M | |
-2.06 | $133.38M | |
-1.22 | $159.50M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like EyePoint Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like EyePoint Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is EyePoint Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for EyePoint Pharmaceuticals, Inc. (EYPT)?
What is the highest PE Ratio for EyePoint Pharmaceuticals, Inc. (EYPT)?
What is the 3-year average PE Ratio for EyePoint Pharmaceuticals, Inc. (EYPT)?
What is the 5-year average PE Ratio for EyePoint Pharmaceuticals, Inc. (EYPT)?
How does the current PE Ratio for EyePoint Pharmaceuticals, Inc. (EYPT) compare to its historical average?